Drug reference

Cangrelor

Antiplatelet · Prevention of cardiovascular events

AntiplateletPrevention of cardiovascular events

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 12 →

AbciximabSevereDatabaseDDInter
AcalabrutinibSevereDatabaseDDInter
AlteplaseSevereDatabaseDDInter
AnisindioneSevereDatabaseDDInter

Mechanism

Cangrelor is a reversible inhibitor of the P2Y12 ADP receptor on the platelet surface. By blocking this key receptor, it attenuates platelet activation and recruitment to sites of vascular injury, thereby reducing thrombotic events.

Indications

Reduction of thrombotic cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received treatment with oral clopidogrel, prasugrel or ticagrelor prior to the procedure and in whom oral therapy with these drugs is not suitable.reduction in the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients undergoing percutaneous coronary intervention who have not been treated with an oral P2Y12 inhibitor and are not given a glycoprotein IIb/IIIa antagonistpercutaneous coronary interventionPatients undergoing PCI following NSTE-ACS

Dosing

Adult: ▶ BY MOUTH ▶ ▶ BY RECTUM Adult: 450–900 mg every 4 hours; maximum 3.6 g per day Acute migraine ▶ ▶ BY MOUTH Adult: 900 mg for 1 dose, to be taken as soon as migraine symptoms develop Prevention of pre-eclampsia in women at moderate or high risk ▶ ▶ BY MOUTH Adult: 75–150 mg once daily from 12 weeks gestation until the birth of the baby Mild to moderate pain (dose approved for use by community prac…